Amyloid-beta (Aβ)-targeting monoclonal antibody trials in early Alzheimer's disease—Clinical outcome with gantenerumab

Bin Xiao; Eng-King Tan

doi:10.1002/ctm2.1559

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (1) : e1559 DOI: 10.1002/ctm2.1559

COMMENTARY

Amyloid-beta (Aβ)-targeting monoclonal antibody trials in early Alzheimer's disease—Clinical outcome with gantenerumab

Bin Xiao ¹^,²^,^†
, Eng-King Tan ¹^,²^,³^,^†

Author information +

History +

PDF

Cite this article

Download citation ▾

Bin Xiao, Eng-King Tan. Amyloid-beta (Aβ)-targeting monoclonal antibody trials in early Alzheimer's disease—Clinical outcome with gantenerumab. Clinical and Translational Medicine, 2024, 14(1): e1559 DOI:10.1002/ctm2.1559

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer's disease. J Prev Alzheimers Dis. 2022;9:197-210.

[2]	van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388:9-21.

[3]	Bateman RJ, Smith J, Donohue MC, et al. Two phase 3 trials of gantenerumab in early Alzheimer's disease. N Engl J Med. 2023;389:1862-1876.

[4]	Karran E, De Strooper B. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nat Rev Drug Discov. 2022;21:306-318.

[5]	Rajah Kumaran K, Yunusa S, Perimal E, Wahab H, Müller CP, Hassan Z. Insights into the pathophysiology of Alzheimer's disease and potential therapeutic targets: a current perspective. J Alzheimers Dis. 2023;91:507-530.

[6]	Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512-527.

[7]	Reish NJ, Jamshidi P, Stamm B, et al. Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke. N Engl J Med. 2023;388:478-479.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.